Review
Biochemistry & Molecular Biology
Mellisa Renteria, Ofek Belkin, Justin Aickareth, David Jang, Majd Hawwar, Jun Zhang
Summary: It is well-known that zinc concentrations are altered in breast cancer patients, with notable zinc hyper-aggregates in breast tumor cells compared to normal cells. However, the mechanisms of zinc accumulation and the consequences of dysregulation are poorly understood. In this review, the authors explore the relationship between cellular zinc regulation/dysregulation, sex steroids, and breast cancer tumorigenesis, with a focus on the CmPn/CmP signaling network.
Article
Endocrinology & Metabolism
Laura J. Mauro, Megan Seibel, Caroline H. Diep, Angela Spartz, Carlos Perez Kerkvliet, Hari Singhal, Elizabeth M. Swisher, Lauren E. Schwartz, Ronny Drapkin, Siddharth Saini, Fatmata Sesay, Larisa Litovchick, Carol A. Lange
Summary: The study reveals that activated PRs support quiescence and pro-survival/pro-dissemination cell behaviors, potentially contributing to early HGSC progression. The results suggest that progesterone may not always confer protection against OC, with potential clinical opportunities to prevent HGSC development by targeting PRs, DREAM, and DYRKs.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Elisa Rossini, Mariangela Tamburello, Andrea Abate, Silvia Beretta, Martina Fragni, Manuela Cominelli, Deborah Cosentini, Constanze Hantel, Federica Bono, Salvatore Grisanti, Pietro Luigi Poliani, Guido A. M. Tiberio, Maurizio Memo, Sandra Sigala, Alfredo Berruti
Summary: Research showed that ER expression was low in ACC cell models, while PgR expression was higher, limiting the clinical approach targeting ER.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Multidisciplinary Sciences
Agnes Osz, Andras Lanczky, Balazs Gyorffy
Summary: This study correlated immunohistochemical results with proteome-level technologies in identifying new prognostic biomarkers for breast cancer treatment selection. By integrating proteomic datasets and establishing a database for breast cancer patients, the study validated protein expression levels and identified candidate proteins as prognostic biomarkers. The large-scale proteomic studies provide sufficient data for validating and ranking potential protein biomarkers.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Lei Duan, Sarah Calhoun, Ricardo E. Perez, Virgilia Macias, Fatima Mir, Melissa R. Pergande, Paolo Gattuso, Jeffrey A. Borgia, Carl G. Maki
Summary: Triple negative breast cancer (TNBC) is an aggressive cancer subtype with limited treatment options and poor prognosis. Research has identified PRCP as a potential therapy target for TNBC, as inhibition of PRCP blocks TNBC cell and tumor growth and inhibits the activity of multiple receptor tyrosine kinases.
Article
Multidisciplinary Sciences
Farrokh Dehdashti, Ningying Wu, Cynthia X. Ma, Michael J. Naughton, John A. Katzenellenbogen, Barry A. Siegel
Summary: The study demonstrates that the change in tumor FFNP uptake after an estradiol challenge is highly predictive of response to endocrine therapy in women with ER+ breast cancer. This finding has significant clinical implications for guiding treatment decisions in breast cancer patients.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Lyudmila Bel'skaya, Elena A. Sarf
Summary: The aim of this study was to determine the metabolic characteristics of saliva based on the molecular biological subtype of breast cancer and the expression levels of HER2, estrogen receptors (ER), and progesterone receptors (PR). The study found that saliva samples from healthy volunteers and patients with different molecular biological subtypes of breast cancer showed differences in 12 biochemical indicators. The composition of saliva in patients with basal-like breast cancer differed the most from other subtypes, indicating a more severe disease and less favorable prognosis. The study also analyzed the individual contribution of HER2, estrogen, and progesterone receptors to changes in saliva composition, finding significant differences compared to a control group.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2022)
Article
Multidisciplinary Sciences
Marian Kalocsay, Matthew J. Berberich, Robert A. Everley, Maulik K. Nariya, Mirra Chung, Benjamin Gaudio, Chiara Victor, Gary A. Bradshaw, Robyn J. Eisert, Marc Hafner, Peter K. Sorger, Caitlin E. Mills, Kartik Subramanian
Summary: Quantitative proteomics was performed on 60 human-derived breast cancer cell line models, resulting in the identification and characterization of subtypes of breast cancer. The datasets were found to conform to known transcriptional subtypes and are freely available for public use. These datasets can be used in combination with other measurements to predict drug response, provide context in signaling pathway models, and identify markers of sensitivity or resistance to therapeutics.
Article
Biotechnology & Applied Microbiology
Eda K. Holl, Victoria Frazier, Karenia Landa, David Boczkowski, Bruce Sullenger, Smita K. Nair
Summary: The study demonstrates that PAMAM-G3 can scavenge NA DAMPs and mitigate their proinflammatory effects, reducing lung metastasis. Treatment with PAMAM-G3 decreases cell-free DNA levels and lung metastasis, associated with reduction in inflammatory immune cell subsets and proinflammatory cytokine levels in the tumor and the periphery. The findings support the potential inclusion of NAS therapy in breast cancer patients undergoing standard-of-care surgery.
Review
Oncology
Darcie D. Seachrist, Lindsey J. Anstine, Ruth A. Keri
Summary: The review discusses the role of FOXA1 in regulating gene activity, cell biology, and the response of breast cancers to hormone therapies. It also highlights the potential for future studies to explore the roles of FOXA1 independent of its regulation of nuclear receptors.
Article
Oncology
Rhonda-Lee F. Aoki, Stephen P. Uong, Scarlett Lin Gomez, Stacey E. Alexeeff, Bette J. Caan, Lawrence H. Kushi, Jacqueline M. Torres, Alice Guan, Alison J. Canchola, Brittany N. Morey, Katherine Lin, Candyce H. Kroenke
Summary: The study found that low neighborhood-level socioeconomic status is significantly associated with LumB and TNBC subtypes, while individual education is only associated with the Her2-e subtype, and individual income is not significantly associated with any breast cancer subtype.
Article
Oncology
Elham Sajjadi, Konstantinos Venetis, Roberto Piciotti, Donatella Gambini, Concetta Blundo, Letterio Runza, Stefano Ferrero, Elena Guerini-Rocco, Nicola Fusco
Summary: The loss of PTEN is associated with tumorigenesis, tumor progression, and therapy resistance in breast cancer patients. Patients with PTEN-low tumors showed significantly enriched hormone receptor negativity and HER2 negativity compared to those with PTEN-retained tumors. The combined analysis of PTEN, HER2, and hormone receptor status provides relevant information for a more precise risk assessment of patients with breast cancer.
Article
Medicine, Research & Experimental
Raman Devarajan, Valerio Izzi, Hellevi Peltoketo, Gunilla Rask, Saila Kauppila, Marja-Riitta Vaisanen, Heli Ruotsalainen, Guillermo Martinez-Nieto, Sanna-Maria Karppinen, Timo Vaisanen, Inderjeet Kaur, Jussi Koivunen, Takako Sasaki, Robert Winqvist, Aki Manninen, Fredrik Warnberg, Malin Sund, Taina Pihlajaniemi, Ritva Heljasvaara
Summary: This study discovered the upregulation of ColXVIII in breast cancer and its association with poor prognosis. ColXVIII was found to promote cancer cell proliferation through its interaction with ErbB receptors and α6 integrin. The study also revealed the importance of ColXVIII in maintaining breast cancer stem cells and tumor progression and metastasis.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Pharmacology & Pharmacy
Terrance Lam, Chantel Mastos, Erica K. Sloan, Michelle L. Halls
Summary: Triple negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes. G protein-coupled receptors, particularly the β2-adrenoceptor, have been identified as potential therapeutic targets. In this study, we investigate how the β2-adrenoceptor promotes TNBC progression and triggers invasion in aggressive TNBC tumor cells. We also discuss the altered organization of GPCRs in tumor cells and the potential for developing targeted anti-cancer GPCR drugs.
PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Multidisciplinary Sciences
Wentao An, Hui Lin, Lijuan Ma, Chao Zhang, Yuan Zheng, Qiuxia Cheng, Chuanshun Ma, Xiang Wu, Zihao Zhang, Yani Zhong, Menghui Wang, Dongfang He, Zhao Yang, Lutao Du, Shiqing Feng, Chuanxin Wang, Fan Yang, Peng Xiao, Pengju Zhang, Xiao Yu, Jin-Peng Sun
Summary: This study identified GPR126 as a membrane receptor for progesterone/17OHP and explored its involvement in potential tumor progression in triple-negative breast cancer.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Biochemistry & Molecular Biology
Katherine A. Leehy, Thu H. Truong, Laura J. Mauro, Carol A. Lange
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2018)
Article
Oncology
Thu H. Truong, Hsiangyu Hu, Nuri A. Temiz, Kyla M. Hagen, Brian J. Girard, Nicholas J. Brady, Kathryn L. Schwertfeger, Carol A. Lange, Julie H. Ostrander
MOLECULAR CANCER RESEARCH
(2018)
Article
Oncology
Tarah M. Regan Anderson, Shihong Ma, Carlos Perez Kerkvliet, Yan Peng, Taylor M. Helle, Raisa I. Krutilina, Ganesh V. Raj, John A. Cidlowski, Julie H. Ostrander, Kathryn L. Schwertfeger, Tiffany N. Seagroves, Carol A. Lange
MOLECULAR CANCER RESEARCH
(2018)
Article
Oncology
Neeraja Sathyamoorthy, Carol A. Lange
Review
Endocrinology & Metabolism
Amy R. Dwyer, Thu H Truong, Julie H. Ostrander, Carol A. Lange
JOURNAL OF MOLECULAR ENDOCRINOLOGY
(2020)
Editorial Material
Endocrinology & Metabolism
Carol A. Lange, Stephen R. Hammes
Summary: The Perspective provides advice for junior researchers in the field of endocrinology, emphasizing the importance of passion, integrity, and innovation in scientific research.
Article
Oncology
Lauryn R. Werner, Katelin A. Gibson, Merit L. Goodman, Dominika E. Helm, Katherine R. Walter, Sean M. Holloran, Gloria M. Trinca, Richard C. Hastings, Howard H. Yang, Ying Hu, Junping Wei, Gangjun Lei, Xiao-Yi Yang, Rashna Madan, Alfredo A. Molinolo, Mary A. Markiewicz, Prabhakar Chalise, Margaret L. Axelrod, Justin M. Balko, Kent W. Hunter, Zachary C. Hartman, Carol A. Lange, Christy R. Hagan
Summary: Clinical studies have linked the use of progestins, synthetic progesterone, to an increased risk of breast cancer. However, the specific role of native progesterone signaling through the progesterone receptor in breast tumor formation remains poorly understood. Research suggests that progesterone can repress certain immune signaling pathways, potentially promoting tumor development in the mammary gland. This study investigated the effects of progesterone on immune cell populations in mouse mammary glands, as well as the impact of progesterone receptor overexpression on tumor formation and immune cell populations. The findings indicate that progesterone treatment and progesterone receptor overexpression are associated with inhibited immune responses, decreased immune cell populations, and an increased risk of mammary gland tumor development in mice.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Endocrinology & Metabolism
Laura J. Mauro, Angela Spartz, Julia R. Austin, Carol A. Lange
Summary: Ovarian cancer is a rare but lethal gynecologic cancer with difficulties in early detection. Progesterone, previously believed to have a protective role, is now being challenged in its singular function. This article integrates historical perspectives, new research findings, and critical interpretations to provide a broader understanding of the role of progesterone and nPR signaling in ovarian cancer.
Article
Oncology
Amy R. Dwyer, Carlos Perez Kerkvliet, Raisa Krutilina, Hilaire C. Playa, Deanna N. Parke, Warner A. Thomas, Branden A. Smeester, Branden S. Moriarity, Tiffany N. Seagroves, Carol A. Lange
Summary: Research shows that in triple-negative breast cancer, the PTK6-driven signaling pathway mediates cell migration via RhoA and AhR signaling pathways, and plays a crucial role in lung metastasis.
MOLECULAR CANCER RESEARCH
(2021)
Article
Oncology
Amy R. Dwyer, Thu H. Truong, Carlos Perez Kerkvliet, Kiran Paul, Peter Kabos, Carol A. Sartorius, Carol A. Lange
Summary: Phospho-PR-B collaborates with IRS-1 to promote the outgrowth of endocrine-resistant and stem-like breast cancer cells. Activation of p-PR can lead to tamoxifen insensitivity. Targeting the crosstalk between phospho-PR and IRS-1 may block the emergence of endocrine resistance.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Carlos Perez Kerkvliet, Amy R. Dwyer, Caroline H. Diep, Robert H. Oakley, Christopher Liddle, John A. Cidlowski, Carol A. Lange
BREAST CANCER RESEARCH
(2020)
Article
Endocrinology & Metabolism
Thu H. Truong, Amy R. Dwyer, Caroline H. Diep, Hsiangyu Hu, Kyla M. Hagen, Carol A. Lange
Review
Endocrinology & Metabolism
Thu H. Truong, Carol A. Lange
Article
Oncology
Alexey A. Leontovich, Mohammad Jalalirad, Jeffrey L. Salisbury, Lisa Mills, Candace Haddox, Mark Schroeder, Ann Tuma, Maria E. Guicciardi, Luca Zammataro, Mario W. Gambino, Angela Amato, Aldo Di Leonardo, James McCubrey, Carol A. Lange, Minetta Liu, Tufia Haddad, Matthew Goetz, Judy Boughey, Jann Sarkaria, Liewei Wang, James N. Ingle, Evanthia Galanis, Antonino B. D'Assoro
BREAST CANCER RESEARCH
(2018)
Article
Oncology
Yao Huang, David J. Burns, Benjamin E. Rich, Ian A. MacNeil, Abhijit Dandapat, Sajjad M. Soltani, Samantha Myhre, Brian F. Sullivan, Carol A. Lange, Leo T. Furcht, Lance G. Laing
